|  |  |
| --- | --- |
| *Este plan de servicios es una guía para el manejo de pacientes con tuberculosis farmacorresistente*. *Las casillas* **🞏** *representan los intervalos de evaluación mínimos recomendados para cada valoraciones.* Por ejemplo, las radiografías de tórax deben realizarse al inicio del estudio, al mes 2, al mes 6, a los 12 meses (1 año) de tratamiento, a los 18 meses de tratamiento ya los 24 meses. Los médicos tratantes y consultores pueden realizar adiciones o modificaciones a estos intervalos según el caso. *Cuando complete una valoración marque la casilla y deje en blanco o escriba "N/A" si no aplica.*  | **Nombre:** **FDN:**  |
| **Mes de tratamiento** |
|  | **1** | **2** | **3** | **4** | **5** | **6** | **7** | **8** | **9** | **10** | **11** | **12** | **13** | **14** | **15** | **16** | **17** | **18** | **19** | **20** | **21** | **22** | **23** | **24** |
| **Fecha** | Base |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |
| **Monitoreo clínico** |
| Frotis de esputo y cultivo | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  |
| CXR (PA y lateral) | [ ]  |  | [ ]  |  |  |  | [ ]  |  |  |  |  |  | [ ]  |  |  |  |  |  | [ ]  |  |  |  |  |  | [ ]  |
| Peso, estatura (IMC)\*  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  |
| Evaluación de toxicidad de medicamentos | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  |
| Pruebas de susceptibilidad a fármacos (DST)  | [ ]  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Órdenes del médico | [ ]  |  |  | [ ]  |  |  | [ ]  |  |  | [ ]  |  |  | [ ]  |  |  | [ ]  |  |  | [ ]  |  |  | [ ]  |  |  | [ ]  |
| **Monitoreo del laboratorio** |
| CMP | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  |
| Mg (BDQ, AK)  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  |
| CBC | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  |
| LFTs | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  |
| TSH (ETA, BDQ, PAS) | [ ]  |  |  | [ ]  |  |  | [ ]  |  |  | [ ]  |  |  | [ ]  |  |  | [ ]  |  |  | [ ]  |  |  | [ ]  |  |  | [ ]  |
| Glucosa >13 años de edad (mensualmente para diabéticos) | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  |
| VIH (CD4, carga viral, si es positivo) | [ ]  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| HBV/HCV | [ ]  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Niveles de medicamentos (según se necesite) Oral/IV/IM | [ ]  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Prueba de embarazo(CFZ, AK) | [ ]  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Otro:       |[ ]   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| *\* Para pacientes pediátricos, consulte la tabla del serie 1 que se encuentra aquí:* [cdc.gov/growthcharts/clinical\_charts.htm](https://www.cdc.gov/growthcharts/clinical_charts.htm) |

|  |  |
| --- | --- |
|  | **Nombre:****FDN:** |
| **Mes de tratamiento** |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | **1** | **2** | **3** | **4** | **5** | **6** | **7** | **8** | **9** | **10** | **11** | **12** | **13** | **14** | **15** | **16** | **17** | **18** | **19** | **20** | **21** | **22** | **23** | **24** |
| **Fecha** | Base |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |
| **Monitoreo de la toxicidad de los fármacos** |
| Ishihara (EMB, LZD) | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  |
| Agudeza visual (EMB, LZD) | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  |
| Cardiaca/ECG (BDQ) Línea de base, 2 semanas, mensualmente | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  |
|  |  |[ ]   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Estado de la salud mental (CS, CFZ) | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  |
| Neuropatía periférica(↑ dosis isoniazida (INH, LZD) | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  |
| Artralgia/dolor en los tendones (FQ) | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  |
| Audiograma (AK) | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  |  |  |  |  |  |  |  |  |  |  |  |  |
| Examen vestibular (AK) | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  |  |  |  |  |  |  |  |  |  |  |  |  |
| Evaluación mensual de toxicidad de medicamentos | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  |

|  |  |  |  |
| --- | --- | --- | --- |
| **Posición** | **Nombre** | **Firma** | **Iniciales** |
| Enfermera principal del caso |       |       |       |
| Médico/clínico tratante de la TB |       |       |       |
| Médico asesor |       |       |       |
| Médico del Centro de Enfermedades Infecciosas de Texas (TCID) |       |       |       |
| Otro:       |       |       |       |
| Otro:       |       |       |       |
| Otro:       |       |       |       |

**Recursos**

**Información general sobre la TB multirresistente a fármacos (TB-MDR)**

* CDC TB Guidelines, Drug-Resistant TB (MDR TB)

[cdc.gov/tb/publications/guidelines/mdr\_tb.htm](https://www.cdc.gov/tb/publications/guidelines/mdr_tb.htm)

* Curry International Tuberculosis Center: A Survival Guide for Clinicians, 3rd edition

[currytbcenter.ucsf.edu/products/cover-pages/drug-resistant-tuberculosis-survival-guide-clinicians-3rd-edition](https://www.currytbcenter.ucsf.edu/products/cover-pages/drug-resistant-tuberculosis-survival-guide-clinicians-3rd-edition)

**Pautas para el tratamiento y monitoreo**

* Heartland Characteristics of Second-Line Drugs for MDR-TB

[heartlandntbc.org/assets/products/card1\_side\_effects\_drug\_interactions.pdf](https://www.heartlandntbc.org/assets/products/card1_side_effects_drug_interactions.pdf)

* Curry International Tuberculosis Center- *Nursing Guide for Managing Side Effects to Drug-resistant TB treatment*

[currytbcenter.ucsf.edu/products/nursing-guide-managing-side-effects-drug-resistant-tb-treatment](https://www.currytbcenter.ucsf.edu/products/nursing-guide-managing-side-effects-drug-resistant-tb-treatment)

* MMWR Provisional CDC Guidelines for the Use and Safety Monitoring of Bedaquiline Fumarate (Sirturo) for the Treatment of Multidrug-Resistant Tuberculosis

[cdc.gov/mmwr/PDF/rr/rr6209.pdf](https://www.cdc.gov/mmwr/PDF/rr/rr6209.pdf)

* CDC Treatment of Multidrug- Resistant Tuberculosis: Bedaquiline Fact Sheet

[cdc.gov/tb/publications/factsheets/treatment/bedaquiline.htm](https://www.cdc.gov/tb/publications/factsheets/treatment/bedaquiline.htm)

* National Tuberculosis Controllers Association Bedaquiline Access Guide

[tbcontrollers.org/docs/bedaquiline/Bedaquiline\_Access\_Guide\_v2.0\_04June2019.pdf](http://www.tbcontrollers.org/docs/bedaquiline/Bedaquiline_Access_Guide_v2.0_04June2019.pdf)

* Challenge TB, USAID, *Guidance on requirements for QTc monitoring and management of drug-resistant TB patients with QT-prolonging agents* [challengetb.org/publications/tools/pmdt/Guidance\_on\_ECG\_monitoring\_in\_NDR\_v2.pdf](https://www.challengetb.org/publications/tools/pmdt/Guidance_on_ECG_monitoring_in_NDR_v2.pdf)

**Referencias para laboratorios**

* A Clinician’s Guide to the TB Laboratory, Heartland National TB Center

[heartlandntbc.org/assets/products/clinicians\_lab\_guide.pdf](http://www.heartlandntbc.org/assets/products/clinicians_lab_guide.pdf)

* CDC New Tool to Diagnose Tuberculosis, *The Xpert MTB/RIF Assay*

[cdc.gov/tb/publications/factsheets/pdf/xpertmtb-rifassayfactsheet\_final.pdf](https://www.cdc.gov/tb/publications/factsheets/pdf/xpertmtb-rifassayfactsheet_final.pdf)

* WHO Frequently Asked Questions on Xpert MTB/RIF Assay

[who.int/tb/laboratory/xpert\_faqs.pdf](https://www.who.int/tb/laboratory/xpert_faqs.pdf)

* CDC Drug Resistant Tuberculosis Laboratory Information

[cdc.gov/tb/topic/laboratory/](https://www.cdc.gov/tb/topic/laboratory/default.htm)

* CDC MDDR MD Drug Users Guide

[cdc.gov/tb/topic/laboratory/mddrusersguide.pdf](https://www.cdc.gov/tb/topic/laboratory/mddrusersguide.pdf)

**Educación para pacientes**

* Hojas informativas de los CDC

[cdc.gov/tb/publications/factsheets/drtb.htm](https://www.cdc.gov/tb/publications/factsheets/drtb.htm), [cdc.gov/tb/publications/factsheets/drtb/mdrtb.htm, y cdc.gov/tb/esp/](https://www.cdc.gov/tb/esp/)

* Bedaquiline (Sirturo) patient facts:

[sirturo.com/sites/default/files/pdf/SIRTURO-patient-tearpad.pdf](https://www.sirturo.com/sites/default/files/pdf/SIRTURO-patient-tearpad.pdf)